IPA also stated that while generics are priced lower than the corresponding brands, it is unfair and unacceptable to link quality with cost.
The Federal Circuit’s refusal to reconsider its ruling forcing Teva to delist asthma-inhaler patents from the FDA’s Orange ...
Late last year we reported on the United States Court of Appeals for the Federal Circuit decision holding that certain device patents should not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback